Cellectis SA
PAR:ALCLS

Watchlist Manager
Cellectis SA Logo
Cellectis SA
PAR:ALCLS
Watchlist
Price: 4.015 EUR -1.35% Market Closed
Market Cap: 289.4m EUR

Cellectis SA
Pre-Tax Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Cellectis SA
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Cellectis SA
PAR:ALCLS
Pre-Tax Income
-$76.1m
CAGR 3-Years
26%
CAGR 5-Years
5%
CAGR 10-Years
-10%
Valneva SE
PAR:VLA
Pre-Tax Income
-€85.6m
CAGR 3-Years
18%
CAGR 5-Years
-26%
CAGR 10-Years
-21%
Nanobiotix SA
PAR:NANO
Pre-Tax Income
-€51.7m
CAGR 3-Years
-6%
CAGR 5-Years
-2%
CAGR 10-Years
-15%
Inventiva SA
PAR:IVA
Pre-Tax Income
-€311m
CAGR 3-Years
-77%
CAGR 5-Years
-65%
CAGR 10-Years
N/A
DBV Technologies SA
PAR:DBV
Pre-Tax Income
-$122.4m
CAGR 3-Years
-7%
CAGR 5-Years
14%
CAGR 10-Years
-16%
Eurobio Scientific SA
PAR:ALERS
Pre-Tax Income
€4.2m
CAGR 3-Years
-58%
CAGR 5-Years
-24%
CAGR 10-Years
N/A
No Stocks Found

Cellectis SA
Glance View

Market Cap
290.4m EUR
Industry
Biotechnology

Cellectis SA engages as a biopharmaceutical company that harnesses the immune system to target and eradicate cancer cells. The company is headquartered in Paris, Ile-De-France and currently employs 345 full-time employees. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.

ALCLS Intrinsic Value
2.473 EUR
Overvaluation 38%
Intrinsic Value
Price

See Also

What is Cellectis SA's Pre-Tax Income?
Pre-Tax Income
-76.1m USD

Based on the financial report for Sep 30, 2025, Cellectis SA's Pre-Tax Income amounts to -76.1m USD.

What is Cellectis SA's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
-10%

Over the last year, the Pre-Tax Income growth was 36%. The average annual Pre-Tax Income growth rates for Cellectis SA have been 26% over the past three years , 5% over the past five years , and -10% over the past ten years .

Back to Top